Development of a Novel Peptide-Based PET Tracer [ 68 Ga]Ga-DOTA-BP1 for BCMA Detection in Multiple Myeloma
Journal of Medicinal Chemistry · 12.09.2024 · 67 (17) · 15118-15130
DOI: 10.1021/acs.jmedchem.4c00759 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 21.08.2024. Verfasst von Lele Song und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China. Hauptthemen laut MEDLINE: B-Cell Maturation Antigen, Multiple Myeloma, Positron-Emission Tomography, Gallium Radioisotopes. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Fujian Medical University, National Natural Science Foundation of China, National High Level Hospital Clinical Research Funding.
Abstract (Originalsprache)
B-cell maturation antigen (BCMA) has emerged as a promising tumor marker for the diagnosis and treatment of multiple myeloma. The noninvasive and rapid detection of BCMA expression in vivo provides significant value in screening and evaluating multiple myeloma patients receiving BCMA-targeted therapy. We identified the BCMA-targeting peptide BP1 from a one-bead-one-compound (OBOC) peptide library using a high-throughput microarray strategy. The BCMA-targeting specificity and affinity of BP1 were assessed by surface plasmon resonance imaging (SPRi), flow cytometry, and confocal imaging. BCMA-positive (H929) and BCMA-negative (K562) subcutaneous tumor models were established and labeled with 68Ga for BP1, followed by PET imaging and biodistribution studies. PET imaging demonstrated that 68Ga-labeled BP1 has significant specific uptake in multiple myeloma, enabling rapid identification of BCMA expression and precise delineation of the disease. Thus, BP1 represents an ideal candidate for multiple myeloma imaging.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China.
- Fujian Provincial Key Laboratory of Brain Aging and Neurodegenerative Diseases, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian 350122, China.
- CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.
ORCID-Profile: Zihua Wang, Lei Kang
Förderung
- Fujian Medical University
- National Natural Science Foundation of China
- National High Level Hospital Clinical Research Funding
- Beijing Municipal Science and Technology Commission
- Beijing Science Foundation for Distinguished Young Scholars
- Joint Funds for the Innovation of Science and Technology Fujian Province
- Scientific and Technological Achievements Transformation Incubation Guidance Fund Project of Peking University First Hospital
Zitieren
APA
Song, L., Jiang, S., Yang, Q., Huang, W., Qiu, Y., Chen, Z., Sun, X., Wang, T., Wu, S., Chen, Y., Zeng, H., Wang, Z., & Kang, L. (2024). Development of a Novel Peptide-Based PET Tracer [ 68 Ga]Ga-DOTA-BP1 for BCMA Detection in Multiple Myeloma. Journal of Medicinal Chemistry, 67(17), 15118-15130. https://doi.org/10.1021/acs.jmedchem.4c00759
Vancouver
Song L, Jiang S, Yang Q, Huang W, Qiu Y, Chen Z, et al. Development of a Novel Peptide-Based PET Tracer [ 68 Ga]Ga-DOTA-BP1 for BCMA Detection in Multiple Myeloma. Journal of Medicinal Chemistry. 2024;67(17):15118-15130. doi:10.1021/acs.jmedchem.4c00759
BibTeX
@article{Song2024,
author = {Song, Lele and Jiang, Sujun and Yang, Qi and Huang, Wenpeng and Qiu, Yongkang and Chen, Zhao and Sun, Xinyao and Wang, Tianyao and Wu, Sitong and Chen, Yongshou and Zeng, Huajie and Wang, Zihua and Kang, Lei},
title = {Development of a Novel Peptide-Based PET Tracer [ 68 Ga]Ga-DOTA-BP1 for BCMA Detection in Multiple Myeloma},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {17},
pages = {15118--15130},
doi = {10.1021/acs.jmedchem.4c00759}
}
EUVIMED